Clinical staging of NSCLC: current evidence and implications for adjuvant chemotherapy. (September 2017)

• Record Type: Journal Article
• Authors: Heineman, David J.; Daniels, Johannes M.; Schreurs, Wilhelmina H.
• Is Part Of: Therapeutic advances in medical oncology. Volume 9:Number 9(2017)
• Page Start: 599
• Page End: 609
• Publication Date: 2017-09
• Subjects: adjuvant -- carcinoma -- chemoradiotherapy -- chemotherapy -- non-small cell lung cancer -- radiosurgery -- radiotherapy -- thoracic surgery; Oncology -- Periodicals; Cancer -- Treatment -- Periodicals; 616.994005
• DOI: 10.1177/1758834017722746
• Languages: English
• ISSNs: 1758-8340

Abstract

Survival of all non-small cell lung cancer (NSCLC) patients is disappointing, with a 5-year survival of 18%. Staging NSCLC patients is crucial because it determines the choice of treatment and prognosis. Clinical staging is a complex process that comes with many challenges and with low accuracy between the clinical and pathological stage. Treatment modalities for stage I–III NSCLC consist of surgical resection, radiotherapy and chemotherapy. This review describes the current evidence on staging and the implications on adjuvant chemotherapy. For stage I disease, staging is most accurate. Primary treatment consists of surgery or stereotactic ablative radiotherapy. When a patient has stage II disease, staging is less accurate because more diagnostic modalities are necessary to stage the mediastinal lymph nodes. Surgery remains the primary treatment modality and platinum-based adjuvant chemotherapy gives a 4% 5-year survival benefit. Staging patients with stage III disease is difficult because of the heterogeneity of the patients. It should be decided if a patient has potentially resectable disease with or without risk of incomplete resection. Induction therapy with chemo(radio)therapy followed by surgical resection or definitive chemoradiotherapy are the treatments of choice. The 5-year survival can reach 44% in selected patients. Decisions in staging and treating patients with NSCLC should be made by a multidisciplinary team with sufficient expertise in all aspects of staging and treatment.